The Second Shoe Drops: What Recent PBM Settlements Mean for Market Access 

On July 14, the Federal Trade Commission secured a settlement agreement with one of the nation’s largest PBMs and its affiliated entities that requires the PBM to adopt changes to its business practices to drive down patients’ out-of-pocket costs, increase transparency and ensure community pharmacies are treated fairly.​ This is the second such deal the FTC has landed, following a similar settlement with another PBM in February 2026​, and it lands in a market that’s already being rewired by the Consolidated Appropriations Act of 2026. 

What’s actually in the settlement

Let’s cut through the press release language. According to the FTC, the settlement locks in place up to $8.5 billion in consumer savings over the next 10 years and unlocks up to $4.5 billion in additional savings for patients over the same 10-year period from point-of-sale rebates.​ Big numbers, sure. But the mechanics matter more than the topline. 

Under the consent order, the PBM will delink fees paid by drug manufacturers to the PBM/Group Purchasing Organizations (GPO) from list prices, provide a standard offering to plan sponsors that ensures rebates will be passed through to members at the point of sale, and allow plan sponsors to transition off rebate guarantees and spread pricing.​ It also bars the organization from unfairly interfering with pharmacies’ ability to work with hub service providers​. 

Why this isn’t just a PBM story​

Here’s the thing. This settlement is not an isolated event. It’s a data point in a much bigger arc. Back in February, President Donald Trump signed the Consolidated Appropriations Act, 2026, which includes significant PBM reforms in the Medicare Part D, Medicare Advantage-Prescription Drug (MA-PD), and commercial markets.​ Among other things, the CAA states that PBMs and PBM affiliates shall not derive remuneration tied to the utilization of covered Part D drugs, other than a bona fide service fee​ and requires PBMs to fully pass through manufacturer rebates to PDP sponsors.​  

So we’ve got legislation and enforcement moving in lockstep. Delinking on one side. Pass-through on the other. And a growing chorus of state-level PBM oversight bills sprinkled on top. As Oliver Wyman recently put it, the traditional rebate-driven market is giving way to a model in which net price, clinical value, and total cost of care are directly evaluated by the economic buyer.​  

That’s a sentence that should be reverberating in market access teams’ heads.  

What This Actually Means 

• Products that have historically relied on rebate-driven positioning may find it increasingly difficult to maintain access. When rebates flow through to the plan sponsor at point of sale, and PBM fees are no longer linked to list price, the whole rationale for high WACs, deep rebates evaporate. 

• Rebates should not be treated as a given, but rather as a strategic inflection point. The rebate economy has been the dominant lever of market access for 35 years. But as one industry veteran put it: the rebate economy isn’t ending tomorrow, but its dominance is no longer guaranteed.  

• If the hub-PBM friction really does dissipate, expect a wave of manufacturer investment in patient services architecture. Hubs matter because they may coordinate the benefits and prior authorization process, help patients understand their out-of-pocket cost options, connect eligible patients with financial assistance, mail or deliver drugs directly to patients and provide drug education, care coordination and refill reminders—This focus is long overdue. 

Zooming out

These recent settlements, the CAA delinking provisions, plus the TrumpRx affordability push; it’s easy to see all as separate news items, but it’s the same story told from different angles. The rebate-driven, opacity-tolerant PBM model that dominated for decades is being disassembled in slow motion, and market access leaders who assume the old rules will hold through the next cycle are going to get caught flat-footed. 

Will patients actually feel $8.5 billion in savings over ten years? I’d love to say yes with confidence. The truth is, savings on paper don’t always land in someone’s copay. The plumbing between a settlement and a pharmacy counter is longer than most people realize. 

But for manufacturers, the more important question may be something else entirely. The real strategic question isn’t whether rebates will disappear. It’s whether rebates become less important than demonstrating a compelling net-cost and total-cost-of-care story. If that transition is underway—and the combination of FTC settlements, federal legislation, and growing transparency requirements suggests it is—the manufacturers that adapt first may be the ones that gain formulary advantage in the next era of market access.